Clinical Trial Update: Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating XL228 given intravenously in patients with advanced malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Lymphoma

Drugs mentioned

• XL228 (XL228)

Snippet

Sponsor: Exelixis | Conditions: Cancer, Lymphoma | Phase 1 | Status: TERMINATED